Group 1 - The core viewpoint of the articles highlights the financial performance and market position of HeFu China, particularly its high PE ratio compared to industry averages [1][2] - As of May 27, HeFu China's closing price was 6.78 yuan, with a PE ratio of 187.01, significantly higher than the industry average of 42.04 and median of 28.02 [1][2] - The total market capitalization of HeFu China is reported at 2.699 billion yuan [1][2] Group 2 - HeFu China's main business involves international trade and after-sales services related to in vitro diagnostic medical devices and consumables, as well as consulting services for hospital information management systems [1] - The latest quarterly report for Q1 2025 shows HeFu China achieved a revenue of 176 million yuan, representing a year-on-year decrease of 26.35%, and a net loss of approximately 6 million yuan, a decline of 184.13% [1] - The gross profit margin for the company stands at 16.71% [1] Group 3 - As of March 31, 2025, HeFu China had 33,527 shareholders, a decrease of 3,450 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

今日焦点中国中车：近期签订合计547.4亿元重大合同 中国中车公告称，公司及下属企业于近期（主要为2024年12月至2025年5月）签订了若干项重大合同， 合计金额约547.4亿元人民币。主要合同包括城市轨道车辆、设备销售及维保合同，动车组销售合同， 动车组高级修合同，风电设备销售合同和储能设备销售合同，机车销售合同以及货车修理合同。上述合 同总金额约占公司中国会计准则下2024年营业收入的22.2%。 阳光诺和：拟购买朗研生命100%股权，股票明日复牌 南方财经5月12日电，阳光诺和(688621.SH)公告称，公司拟通过发行股份及可转换公司债券购买资产并 募集配套资金，购买利虔、朗颐投资等38名朗研生命股东持有的朗研生命100%股权。并向不超过35名 特定投资者发行股份募集配套资金。朗研生命专注于高端化学药及原料药的研发、生产和销售，并对外 提供药品生产服务，在高端化学药、原料药等领域深耕多年，已经形成了较为成熟的医药生产体系。公 司股票将于5月13日开市起复牌。 沃尔核材：筹划发行H股股票并申请在香港联交所主板上市 沃尔核材公告称，公司拟发行H股股票并申请在香港联交所主板挂牌上市，以推进国际化战略，提升 ...

Group 1 - Aikolan's controlling shareholder Liu Yi terminated the share transfer agreement for 4 million shares, which represents 5% of the company's total share capital, with no change in control [1] - Wancheng Group announced a cash dividend of 4.00 yuan per 10 shares, totaling 71.9959 million yuan, with the record date on May 19, 2025 [1] - Wanda Film plans to invest in Lezi Tiancheng and engage in strategic cooperation, acquiring a total of 7% equity in the company [2] Group 2 - China Resources Double Crane's subsidiaries received approval for two drugs, indicating progress in their product pipeline [3] - Fosun Pharma's subsidiary's drug was included in the breakthrough therapy program, highlighting its innovative potential [4] - Zhongheng Group's subsidiary received approval for naloxone injection, enhancing its product offerings [5] Group 3 - Shenzhen Airport reported a passenger throughput of 5.3202 million in April, a year-on-year increase of 23.50% [8] - Hangzhou Bank successfully issued 5 billion yuan in technology innovation bonds, aimed at supporting tech innovation [10] - Jiuzhou Pharmaceutical received approval for a raw material drug used in treating severe depression, expanding its product range [12] Group 4 - Aihua Group reported a 25.38% decline in revenue for the first four months of the year, indicating potential challenges [27] - Changhua Group received a project designation notice from a well-known new energy vehicle company, with an expected total sales amount of approximately 108 million yuan [28] - Nanchao Food reported a slight revenue decrease of 0.98% in April, reflecting market conditions [30]

公司 2025 年 1-4 月合并营业收入人民币 24,823.15 万元，较去年同期下降 25.38%，2025 年 1-3 月合并营业收入较去年同期下降 26.35%，下降幅度收窄 0.97%，营收情况持续改善。 特此公告。 合富（中国）医疗科技股份有限公司董事会 2025 年 5 月 13 日 1 证券代码：603122 证券简称：合富中国 公告编号：临 2025-018 合富（中国）医疗科技股份有限公司 2025 年 1-4 月累计营业收入简报 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 合富（中国）医疗科技股份有限公司（以下简称"公司"）之间接控股股东 合富医疗控股股份有限公司（以下简称"合富控股"）为台湾地区证券柜台买 卖中心上柜公司，合富控股需按照台湾证券交易所相关规定，每月披露营业收 入数据。为使 A 股投资者能够及时了解公司的经营情况，本公司亦同步在上海 证券交易所指定的信息披露媒体《上海证券报》、《中国证券报》、《证券时报》、 《证券日报》和上海证券交易所网站（http://www.sse.com.cn ...

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of HeFu China, particularly its high PE ratio compared to industry averages [1][2] - HeFu China's closing price on May 7 was 6.63 yuan, with a PE ratio of 182.87, marking a new low in 21 days, and a total market capitalization of 2.639 billion yuan [1] - The average PE ratio for the pharmaceutical commercial industry is 36.32, with a median of 27.46, positioning HeFu China at 26th place within the industry [1][2] Group 2 - As of March 31, 2025, HeFu China had 33,527 shareholders, a decrease of 3,450 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The main business of HeFu China involves international trade and after-sales service of in vitro diagnostic medical devices and consumables, as well as consulting services for hospital information management systems [1] - In the latest quarterly report for Q1 2025, HeFu China reported revenue of 176 million yuan, a year-on-year decrease of 26.35%, and a net loss of approximately 6 million yuan, representing a year-on-year decline of 184.13%, with a gross profit margin of 16.71% [1]

A股医药商业板块异动拉升，嘉事堂封板涨停，瑞康医药、润达医疗、漱玉平民、合富中国、海王生物 等跟涨。 ...

扫码关注合富中国 合富（中国）医疗科技股份有限公司 上海市徐汇区虹漕路 456 号光启大厦 T（86）400-678-8855 www.cowealth.com 上海证券交易所 股票简称及代码：合富中国 603122 合富中国 2024 年度 可持续发展报告 合 富 中 国 2024 年 度 可 持 续 发 展 报 告 1 合富中国 2024 年度可持续发展报告 CMC 2024 Sustainability Report 报告发行时间 ：2025年4月 关于本报告 本报告编制 此为合富（中国）医疗科技股份有限公司（下称"合富中国"、 "本公司"、"公司"或"我们"）2024年的可持续发展报告（下称 本报告），旨在呈现本公司可持续发展的政策与绩效，以回应 利益相关方的期待。 本报告的编写参考以下报告指引 ： 我们以负责任的态度向利益相关方披露公司在经济、环境及社 会上的政策及表现，并展现本公司对落实可持续发展的决心。 报告范畴 本报告为年度报告，报告期为2024年1月1日至2024年12月31 日，提供合富中国重要营运地点的企业可持续发展管理与绩效 表现，主体范围与本公司年报一致。本报告部分统计资料引用 自年 ...

一、董事会会议召开情况 合富（中国）医疗科技股份有限公司（以下简称"公司"）第二届董事会第 十五次会议于 2025 年 4 月 29 日下午在上海市虹漕路 456 号光启大楼 20 楼公司 董事会议室/台北市敦化南路 2 段 76 号 23 楼以现场与视讯相结合的方式召开， 会议通知于 2025 年 4 月 24 日以电子邮件或书面方式发出。本次会议由董事长李 惇先生主持，应到董事 7 人，实到董事 6 人，其中委托出席董事 1 人，非独立董 事王琼芝女士因工作安排委托董事长李惇先生代为出席本次会议并行使表决权； 缺席会议的董事 1 人，独立董事 Stanley Yi Chang 先生因个人身体健康原因缺 席本次会议。监事和部分高级管理人员列席了会议。会议的召开符合法律法规、 《公司法》及《公司章程》的规定，会议决议合法、有效。 与会董事认真审议了所有议案，经书面投票表决，形成了如下决议： 二、董事会会议审议情况 1 证券代码：603122 证券简称：合富中国 公告编号：临 2025-017 合富（中国）医疗科技股份有限公司 第二届董事会第十五次会议决议公告 本公司董事会及除独立董事 Stanley Yi C ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥175,735,762.62, a decrease of 26.35% compared to ¥238,622,168.70 in the same period last year[3] - The net profit attributable to shareholders was -¥6,001,192.11, representing a decline of 184.13% from a profit of ¥7,133,561.76 in the previous year[3] - Basic earnings per share decreased by 200.00% to -¥0.02 from ¥0.02 in the previous year[3] - Total revenue for Q1 2025 was RMB 175.74 million, a decrease of 26.4% compared to RMB 238.62 million in Q1 2024[16] - Net profit for Q1 2025 was a loss of RMB 5.89 million, compared to a profit of RMB 7.02 million in Q1 2024[17] - The company reported a total comprehensive loss of RMB 6.20 million in Q1 2025, compared to a comprehensive income of RMB 6.49 million in Q1 2024[17] Cash Flow and Operating Activities - The net cash flow from operating activities improved to ¥38,492,423.52, compared to -¥52,712,185.37 in the same period last year, indicating effective supply chain management[3] - Operating cash flow for Q1 2025 was RMB 38.49 million, a significant improvement from a negative cash flow of RMB -52.71 million in Q1 2024[19] - The company experienced a net cash outflow from investing activities of RMB 83.57 million in Q1 2025, compared to RMB -6.79 million in Q1 2024[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,552,107,798.54, an increase of 3.88% from ¥1,494,072,333.88 at the end of the previous year[6] - The company's current assets totaled RMB 1,321,354,869.58, compared to RMB 1,290,982,272.60 at the end of 2024, indicating an increase of about 2.4%[13] - Total liabilities rose to RMB 383,911,181.84 from RMB 319,439,793.98, marking an increase of approximately 20.2%[14] - The company's equity attributable to shareholders decreased to RMB 1,165,160,559.65 from RMB 1,171,469,561.57, a decline of about 0.5%[14] - The total current liabilities increased to RMB 380,399,337.40 from RMB 318,701,872.45, reflecting a growth of approximately 19.4%[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,527[10] - The company has not reported any changes in the top 10 shareholders or their participation in margin financing activities[12] Research and Development - Research and development expenses for Q1 2025 were RMB 635.17 thousand, a decrease of 30.6% from RMB 915.00 thousand in Q1 2024[16] Inventory and Receivables - The company reported a significant increase in inventory, which rose to RMB 208,529,372.68 from RMB 201,881,192.88, an increase of about 3.3%[13] - Accounts receivable increased to RMB 760,740,608.19 from RMB 738,471,128.95, representing a rise of approximately 3%[12] Non-Recurring Gains and Losses - Non-recurring gains and losses for the period totaled ¥43,497.32 after tax adjustments[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥6,044,689.43, a decline of 191.02% from ¥6,641,379.02 in the previous year[3] Equity and Return Metrics - The weighted average return on equity decreased to -0.51%, down 1.12 percentage points from 0.61% in the previous year[6] - The company's non-current assets totaled RMB 230,752,928.96, up from RMB 203,090,061.28, indicating an increase of approximately 13.6%[13]

证券代码：603122 证券简称：合富中国 公告编号：临 2025-016 公司新一届董事会、监事会换届选举工作完成前，公司第二届董事会和监事 会全体成员、董事会各专门委员会委员及高级管理人员将按照法律法规和《公司 章程》的规定继续履行职责和义务。 公司董事会及监事会延期换届不会影响公司正常生产经营。公司将积极推进 董事会、监事会换届选举工作进程，并按照相关规定及时履行信息披露义务。 二、独立董事任期届满辞任情况 根据《上市公司独立董事管理办法》、《公司章程》等相关规定，上市公 司独立董事占董事会成员的比例不得低于三分之一，独立董事在上市公司连 续任职时间不得超过六年。公司现任独立董事 Stanley Yi Chang 先生、雷 永耀先生以及周露露女士任期将于 2025 年 4 月 27 日届满且连任时间将满六 年。近日，公司董事会收到独立董事 Stanley Yi Chang 先生、雷永耀先生 以及周露露女士的辞呈，提请辞去独立董事及董事会下属专门委员会的相关 职务，辞职后 Stanley Yi Chang 先生、雷永耀先生、周露露女士将不再担 任公司的任何职务。具体辞任情况如下： 独立董事 Stanley ...